Erudio Healtherudio.com
Sponsor
Takeda trials: what clinicians said in public
No HCP commentary report on a trial sponsored by Takeda yet. Erudio has found public clinician commentary on 15 clinical trials sponsored by Takeda, including ALTA-1L, EXCLAIM-2, TOURMALINE-MM1 and TOURMALINE-MM3. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (Takeda; Millennium Pharmaceuticals, Inc.; Ariad Pharmaceuticals). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| ALTA-1L NCT02737501 · Ariad Pharmaceuticals DeepView → | ALK inhibitor-naive advanced ALK-positive non-small cell lung cancer | Phase 3 | Deep | View | |||
| EXCLAIM-2 NCT04129502 · Takeda DeepView → | first-line EGFR exon 20 insertion-positive metastatic NSCLC | Phase 3 | Deep | View | |||
| TOURMALINE-MM1 NCT01564537 · Takeda DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| TOURMALINE-MM3 NCT02181413 · Takeda DeepView → | multiple myeloma following autologous stem cell transplant | Phase 3 | Deep | View | |||
| ALTA-3 NCT03596866 · Takeda FocusedView → | crizotinib-resistant advanced ALK-positive non-small-cell lung cancer | Phase 3 | Focused | View | |||
| NCT02716116 NCT02716116 · Takeda FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| J-ALTA NCT03410108 · Takeda FocusedView → | ALK-positive advanced NSCLC | Phase 2 | Focused | View | |||
| ALTA-2 NCT03535740 · Ariad Pharmaceuticals FocusedView → | ALK-positive advanced NSCLC progressed on alectinib or ceritinib | Phase 2 | Focused | View | |||
| C16008 NCT01383928 · Millennium Pharmaceuticals, Inc. FocusedView → | newly diagnosed multiple myeloma | Phase 1/Phase 2 | Focused | View | |||
| PARADIGM NCT02394795 · Takeda FocusedView → | first-line RAS wild-type metastatic colorectal cancer | Phase 3 | Focused | View | |||
| NCT01850524 NCT01850524 · Millennium Pharmaceuticals, Inc. FocusedView → | Not given | Phase 3 | Focused | View | |||
| C16020 NCT02046070 · Millennium Pharmaceuticals, Inc. FocusedView → | newly diagnosed or relapsed/refractory multiple myeloma | Phase 2 | Focused | View | |||
| NCT03589326 NCT03589326 · Takeda FocusedView → | Not given | Phase 3 | Focused | View | |||
| NCT04419649 NCT04419649 · Takeda FocusedView → | anemia in very low/low/intermediate risk myelodysplastic syndromes | Phase 2 | Focused | View | |||
| ELRiSE MDS NCT07422480 · Takeda FocusedView → | Not given | Phase 3 | Focused | View | |||